Not for human use, for research purposes only
Ipamorelin + CJC-1295 Blend - Ipamorelin + CJC-1295 (no DAC) is a GHRH/GHRP peptide blend

Ipamorelin + CJC-1295 Blend

5.0 (2)

Ipamorelin + CJC-1295 (no DAC) is a GHRH/GHRP peptide blend that combines a GHRH receptor agonist with a ghrelin receptor (GHS-R1a) agonist.

GH Axis
In Stock

1 × 10mg vial (5mg + 5mg)

Checking availability…

Total Price

฿1700

VisaMastercardApple PayKlarnaiDEALBitcoinUSDT& more more: Bancontact, Open Banking, Cash App, Afterpay, more coinsCrypto −5%Encrypted checkout

For research & laboratory use only. Not for human consumption.

Shipping: free within Thailand, ฿700 worldwide. Added at checkout. Delivery times & countries

Half-Life

CJC-1295 no DAC: ~30min; Ipamorelin: ~2h

Combined Formulation

CJC-1295 no DAC (5mg) and Ipamorelin (5mg) in a single 10mg vial

Two Receptor Classes

GHRH receptor (Gs-coupled) and ghrelin receptor GHS-R1a (Gq-coupled)

Short Half-Lives

CJC-1295 no DAC ~30 min, Ipamorelin ~2 h

Mechanism of Action

This blend combines a GHRH analogue with a selective GHRP. CJC-1295 without DAC binds the pituitary GHRH receptor, a Gs-coupled receptor, raising cAMP in somatotrophs. Ipamorelin binds the ghrelin receptor GHS-R1a, a Gq-coupled receptor signalling through phospholipase C, and is described as selective because, unlike GHRP-2 and GHRP-6, it is reported not to co-stimulate ACTH, cortisol or prolactin release in preclinical studies. Both peptides have short half-lives.

Receptor Pharmacology of the Ipamorelin + CJC-1295 Blend

This blend combines a GHRH receptor agonist with a ghrelin receptor agonist. Pituitary somatotrophs sit at the crossing point of several regulatory inputs:

Stimulatory:

  • GHRH (via the GHRH receptor, Gs-coupled) raises cAMP and activates PKA
  • Ghrelin and GHRPs (via GHS-R1a, Gq-coupled) raise intracellular Ca2+ and drive vesicle exocytosis

Inhibitory:

  • Somatostatin (via SSTR, Gi-coupled) opposes cAMP and restrains release

CJC-1295 without DAC and Ipamorelin each engage one of the two stimulatory arms. The two peptides act on separate receptors and second-messenger systems of the same cell type.

Half-Lives

CJC-1295 no DAC has a half-life of roughly 30 minutes and Ipamorelin of roughly 2 hours. CJC-1295 carrying the DAC modification, by contrast, has a multi-day half-life.

Downstream Signalling

Released growth hormone binds the GH receptor and signals through JAK2/STAT5, and hepatic IGF-1 expression follows.

Kit Contents and Storage

Milo-Lab supplies the blend as a single 10mg vial containing 5mg CJC-1295 without DAC and 5mg Ipamorelin.

Lyophilised vials: store at -20°C, protected from light.

For research purposes only. Not for human consumption.

Product FAQs

Customer Reviews

5.0 (2)

Good choice Good package

Thxw Verified
2026-09-09

Fast delivery, good customer support. product is clean.

Mr. S. Verified
2026-08-26

Related Products